1. Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation
- Author
-
Saeed, Omar, Zhang, Shuaiqi, Patel, Snehal R, Jorde, Ulrich P, Garcia, Mario J, Bulcha, Nurilign, Gupta, Tanush, Xian, Ying, Matsouaka, Roland, Shah, Shreyansh, Smith, Eric E, Schwamm, Lee H, and Fonarow, Gregg C
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Brain Disorders ,Aging ,Heart Disease ,Stroke ,Cardiovascular ,Aged ,Anticoagulants ,Atrial Fibrillation ,Brain Ischemia ,Heart Failure ,Humans ,Ischemic Stroke ,Medicare ,United States ,Oral Anticoagulation ,Mortality ,Hemorrhage ,Cardiorespiratory Medicine and Haematology ,Nursing ,Cardiovascular System & Hematology ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundThe safety and effectiveness of oral anticoagulation (OAC) after an ischemic stroke in older patients with heart failure (HF) without atrial fibrillation remains uncertain.MethodsUtilizing Get With The Guidelines Stroke national clinical registry data linked to Medicare claims from 2009-2014, we assessed the outcomes of eligible patients with a history of HF who were initiated on OAC during a hospitalization for an acute ischemic stroke. The cumulative incidences of adverse events were calculated using Kaplan-Meier curves and adjusted Cox proportional hazard ratios were compared between patients discharged on or off OAC.ResultsA total of 8,261 patients from 1,370 sites were discharged alive after an acute ischemic stroke and met eligibility criteria. Of those, 747 (9.0%) were initiated on OAC. Patients on OAC were younger (77.2±8.0 vs. 80.5±8.9 years, p
- Published
- 2021